Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory. The Company's novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Natera's statistical algorithms combine these measurements with data available from the broader scientific community to detect a wide range of serious conditions with best-in-class accuracy and coverage. The Company's goal is to develop and commercialize non- or minimally-invasive tests to determine the likelihood of a wide range of genetic conditions. Natera's tests are used for the detection of genetic variations covering a broad set of diseases, such as Down syndrome, which can enable diagnosis and treatment.

Type
Public
HQ
San Carlos, US
Founded
2004
Size (employees)
852 (est)
Website
natera.com
Natera was founded in 2004 and is headquartered in San Carlos, US
Report incorrect company information

Key People/Management at Natera

Matthew Rabinowitz

Matthew Rabinowitz

CEO
Jonathan Sheena

Jonathan Sheena

CTO

Natera Office Locations

Natera has offices in Herndon, San Francisco, Jersey, Raleigh and in 20 other locations
San Carlos, US (HQ)
410 201 Industrial Rd
Show all (24)
Report incorrect company information

Natera Financials and Metrics

Natera Financials

Natera's revenue was reported to be $217.07 m in FY, 2016 which is a 14% increase from the previous period.
USD

Revenue (Q3, 2017)

56.7 m

Net income (Q3, 2017)

(27.1 m)

EBIT (Q3, 2017)

(25 m)

Market capitalization (18-Apr-2018)

593.4 m

Cash (30-Sep-2017)

11.2 m
Natera's current market capitalization is $593.4 m.
Annual
USDFY, 2015FY, 2016

Revenue

190.4 m217.1 m

Revenue growth, %

14%

General and administrative expense

109.6 m136.1 m

R&D expense

27.7 m41.9 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

45.1 m44.9 m61.9 m52 m53.9 m46.9 m53.6 m56.7 m

General and administrative expense

28.1 m27.9 m30.4 m33.2 m34.9 m37.6 m34.3 m

R&D expense

8.8 m10.3 m11.3 m12.7 m11.8 m

Operating expense total

28.1 m27.9 m39.2 m43.5 m46.3 m50.2 m46.1 m
Annual
USDFY, 2015FY, 2016

Cash

28.9 m15.3 m

Accounts Receivable

154.8 m218.6 m

Inventories

5.3 m7.1 m

Current Assets

250.7 m174.1 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

62.2 m196.2 m34 m16.6 m25.3 m9.1 m7.1 m11.2 m

Inventories

14.6 m12.7 m6.7 m8.9 m9.2 m8.2 m7.4 m6.4 m

Current Assets

85.8 m246.3 m248.6 m237.2 m212.3 m140.2 m123.1 m169.2 m

PP&E

15 m14 m15.1 m19.1 m25.6 m31.8 m31.3 m
Annual
USDFY, 2015FY, 2016

Net Income

(70.3 m)(95.8 m)

Depreciation and Amortization

5.5 m6.2 m

Inventories

(3.8 m)(2.1 m)

Accounts Payable

1.4 m1.3 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(19.7 m)(17.6 m)(8.7 m)(23.2 m)(26 m)(36 m)(27.1 m)

Inventories

14.6 m12.7 m6.7 m8.9 m9.2 m8.2 m6.4 m

Accounts Payable

8.9 m6.1 m9 m9.2 m8.8 m6.6 m3.8 m
USDY, 2017

Revenue/Employee

66.5 k

Financial Leverage

6.8 x
Show all financial metrics
Report incorrect company information

Natera News and Updates

Liquid Biopsy Market: Industry Latest Trends & Global Outlook 2016-2024

Main factors fueling the demand for diagnostics using liquid biopsy are growing incidences of lung cancer, gastrointestinal cancer, and breast cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday

Noninvasive Prenatal Testing Market Size to Expand at 10.2% CAGR by 2024

At present, Persistence Market Research values the global noninvasive prenatal testing market at just over US$ 665 Mn, and expects the market to incur revenue growth at an impressive 10.2% CAGR. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information